No Data
Halozyme Says European Commission Approves Darzalex Co-Formulated With Enhanze to Treat Multiple Myeloma
Express News | European Commission Approved Subcutaneous Darzalex® (Daratumumab)-Based Quadruplet Regimen for the Treatment of Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
European Commission Approved Subcutaneous DARZALEX (Daratumumab)-based Quadruplet Regimen for the Treatment of Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
Morgan Stanley Lists 'Attractive' Small-cap Stocks With Positive ROE and Momentum
Johnson & Johnson's Janssen Says Subcutaneous Rybrevant Approved for 2 Indications in EU
Halozyme Therapeutics Announced That Janssen-Cilag International NV, A J&J Company, Has Received European Commission Marketing Authorization Of The Subcutaneous Formulation Of RYBREVANT, In Combination With LAZCLUZE, For The First-Line Treatment Of...